Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial

This phase III, non-randomized, open-label, multi-center study (NCT01827839) evaluated the immunogenicity and safety of an adjuvanted recombinant subunit herpes zoster (HZ) vaccine (HZ/su) in adults aged ≥ 50 y with prior physician-documented history of HZ. Participants (stratified by age: 50–59, 60...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Hum Vaccin Immunother
Main Authors: Godeaux, Olivier, Kovac, Martina, Shu, Daniel, Grupping, Katrijn, Campora, Laura, Douha, Martine, Heineman, Thomas C., Lal, Himal
Formato: Artigo
Idioma:Inglês
Publicado: Taylor & Francis 2017
Assuntos:
Research Papers
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5443374/
https://ncbi.nlm.nih.gov/pubmed/28068212
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2016.1265715
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares